Obstructive sleep apnoea: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 6
• NRF2 0
• NLRP3 1
• HIF-1 0
• AKT 0
• GIP 0
• JAK 0
• MAPK 0
• PI3K 0
• SGLT2 0
• STAT3 0
• TLR4 0
• AMPK 0
• AQP4 0
• BDNF 1
• CTNNB1 0
• MAPT 0
• METTL3 0
• SIRT1 0
• TIGIT 0
• ALK 0
• CD20 0
• CFTR 0
• CGRP 0
• ERK 0
• GPX4 0
• HDAC 0
• HMGB1 0
• IL-6 0
• JNK 0
• mTOR 0
• PCSK9 0
• PINK1 0
• PKM2 0
• PPAR 0
• STING 0
• TP53 0
• YAP 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · F31

  Slow-Wave Sleep Enhancement to Treat Epilepsy

  University of California at Davis· Davis, United States· US$43,749 awarded in fiscal year 2026· until Sept 2029

• NIH NIA · R56

  Breathing therapy to improve clearance of brain toxins in elder poor sleepers

  University of Miami School of Medicine· Coral Gables, United States· US$635,301 awarded in fiscal year 2026· until Aug 2027

• NIH NHLBI · R01

  Intermittent Hypoxemia in Early Life among Preterms (I-HELP) Sleep

  Northwestern University· Chicago, United States· US$2,332,060 awarded in fiscal year 2026· until Jun 2030

• NIH NHLBI · R43

  Feasibility testing of a novel in-ear sensor system for ambulatory neurological sleep monitoring to enable accessible diagnosis of sleep disorders

  Eerdx Inc· Denver, United States· US$314,318 awarded in fiscal year 2026· until Aug 2027

• NIH NICHD · R01

  The Benefits, Risks, and Long-term Impact of GLP-1 Receptor Agonists in Children

  Indiana University Indianapolis· Indianapolis, United States· US$1,589,979 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  from DEep BREaths to deep Memories: the role of respiration in stabilizing memories during sleep (DEBREM)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Germany· EU contribution €189,687· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

6 of 299 running projects, newest first. Listed amounts together: US$190.8m + €189.7k.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea

  NCT07846865· Woolcock Institute of Medical Research· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 2
• Mendelian Randomization Analysis 16
• Gene Expression Profiling 13
• Sequence Analysis, RNA 4
• Exome Sequencing 1
• Proteomics 6
• Metabolomics 6
• Flow Cytometry 1
• Immunohistochemistry 1
• Positron-Emission Tomography 7
• Magnetic Resonance Imaging 47
• Machine Learning 50
• Deep Learning 16
• Cohort Studies 96
• Genome-Wide Association Study 15

• Peripheral Mononuclear Cells Metabolomics in Obstructive Sleep Apnea Syndrome (OSAS): An Exploratory Pilot Study of Immunometabolic Signatures.

  Int J Mol Sci, Aug 2026

• Metagenomic and metabolomic profiling in primary aldosteronism with coexisting obstructive sleep apnea.

  Front Endocrinol (Lausanne), Jul 2026

• Chronic intermittent hypoxia exacerbates hepatic steatosis in a microbiota-dependent manner in lean mice.

  mSystems, May 2026

• Multi-omics analysis of gut microbiota and metabolome reveals potential biomarkers in pediatric snoring.

  BMC Microbiol, Mar 2026

• Effect of chronic intermittent hypoxia on apoptosis based on microbiome-based co-metabolomics.

  Exp Neurol, Mar 2026

• Urinary Metabolomic Profiling in Obstructive Sleep Apnoea Hypopnoea Syndrome.

  J Sleep Res, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.